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Ulcerative colitis (UC) and Crohn’sdisease (CD), the most predomi-nant manifestations of inflamma-
tory bowel diseases (IBD), are accelerat-
ing major health problems. Although
the aetiology of IBD remains elusive, a
great deal of work has been carried out
in successfully identifying some of the
pathological and clinical profiles that
are perturbed in these patients. This has
led to the description of some of the
molecular mechanisms that may
underlie the idiopathic inflammation
encountered in IBD. More recently,
gene families and clusters which may be
implicated in the onset of IBD, albeit
in a limited manner, have been dis-
covered.
Cytokines such as interleukin (IL)-1,
IL-6, tumour necrosis factor α (TNF-α),
and interferon γ among others, have
been shown to maintain the highly
chronic inflamed state of the bowel, if
not actually causing the onset of this
condition. Hence one (major) effort to
uncouple the vicious circle and to com-
bat this disease has been to eliminate or
diminish the effects of these cytokines.
The use of molecules blocking cytokine
receptor interactions, by disrupting the
means of cytokine activity (for example,
inhibiting nuclear factor κB using anti-
sense molecules), is well documented.
Taken together, there is an increasing
demand to further understand the sig-
nalling mechanisms of various cyto-
kines.
In most instances, the mitogen acti-
vated protein kinase (MAPK) family of
enzymes are involved in transducing the
cytokine signal within the epithelial cell
of the gut mucosa. These enzymes are
predominantly serine/threonine kinases
and are activated via phosphorylation of
these moieties in a well regulated cas-
cade, leading to activation of specific
transcription factors and subsequent
target genes. Nevertheless, a linear cas-
cade of kinase activation appears un-
likely as other “peripheral” effectors
most likely will also be induced and
should therefore be included in any
therapeutic regime directed towards
cytokine signalling pathways.
A number of such anti-inflammatory
therapies undergoing pharmacological
and preclinical studies have targeted
numerous serine/threonine kinases. Of
these kinases, activation of p38 MAPK
by a plethora of extracellular stimuli,
including cellular stress, osmotic shock,
and proinflammatory cytokines, is well
documented. A number of p38 kinase
inhibitors have been identified,
including a dominant negative p38 mol-
ecule, but harnessing use of small
molecule inhibitors appears to be the
most promising in the present clinical
setting.
Initially identified as an inhibitor of
cytokine release (for example, TNF), the
pyridinilimidazole compound SB203580
was later identified as an inhibitor of
p38 kinase activity. This and other p38
inhibitors (for example, CNI-1493,
ML3163) have been previously shown to
be efficient in reducing the severity of
inflammatory disease, including endo-
toxin induced mortality and collagen
induced arthritis in mouse models. In
this issue of Gut, ten Hove and
colleagues1 have queried the efficacy of
this compound in blocking trinitroben-
zene sulphonic acid (TNBS) induced
colitis [see page 507]. The results,
although not entirely unexpected, have
posed some interesting questions re-
garding p38 function, especially in IBD.
Briefly, limited reduction in IL-12 cyto-
kine production was observed, with no
discernible loss of TNF expression in
colon homogenates. Furthermore, in SB
203580 treated TNBS mice, wasting was
more significant but colonic weight was
higher despite a decrease in cell num-
bers in colonic lymph nodes compared
with controls. Thus one of the observed
effects may be to intervene on cell fate,
be it to stop cell growth or induce
apoptosis. Hence in this instance it
appears that although some of the
inflammatory agents are affected, thus
in part abrogating the inflammatory
process, it is not sufficient to completely
ameliorate inflammation by p38 inacti-
vation.
A number of explanations for the lack
in efficacy have been suggested. One
explanation assumes that “disease” initi-
ating signalling pathways, bypassing the
p38 block, precede p38 activation. An-
other invokes the function of upstream
activators which can regulate inflamma-
tion in a p38 independent manner in
TNBS induced colitis.
The precise nature of colitis induction
by TNBS is unknown and thus other
“inflammatory pathways” could also be
activated by such an agent. To date, at
least five isoforms of p38, two of which
are ubiquitous, have been identified.
Although regarded as a selective inhibi-
tor of p38, extensive studies have not
revealed a pan isoform inhibition
through SB 203580. Hence some of the
effects seen in this study may be due to
the nature of the inhibitor, primarily
those pertaining to antiproliferation and
cell cycle regulation. The results pre-
sented by ten Hove et al are therefore of
general interest and increased research
activity in this area is certainly much
needed.
One other alternative explanation is
the less studied role of p38 induced
downregulation of signalling. In the
absence of an active p38 MAPK, negative
feedback regulation of inflammatory
signalling may well be hampered. In
these instances, not only intercellular (as
discussed by ten Hove and colleagues1)
but also intracellular cross talk may be
affected. At present the nature of the lat-
ter remains to be elucidated but given
the importance of switch off mecha-
nisms, this field of enquiry will no doubt
receive warranted attention in the near
future.
IBD being multifactorial speaks for a
complexity that transcends the pertur-
bation of just one (p38) among many
kinases. Hence in the gut, merely inacti-
vating p38 may not be sufficient to amel-
iorate the inflammatory process. Alter-
natively, p38 may still have a kinase
independent role (as postulated for
Jak2), involved in recruitment and struc-
tural modification. This function may
contribute to the enhanced severity of
the disease in this study as p38 itself is
still phosphorylated.
The work presented by ten Howe et al
in this issue of Gut1 illuminates the com-
plexity of signalling mechanisms that
must be unravelled before we can obtain
a coherent picture of diseases such as
IBD. Having acquired this information,
but only then, can the development of
new drugs be expected. Until then the
question as to whether deactivating p38
suffices in ameliorating (TNBS induced)
colitis remains to be answered.
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In this issue of Gut, Domon-Dell andcolleagues1 report the influence ofbutyrate on the intestinal homeobox
gene Cdx2 [see page 525]. Butyrate is a
byproduct of fibre fermentation by co-
lonic bacteria and is known to be a sub-
strate for colonocytes. Over the last few
years there has been increasing interest
in the function of genes involved in con-
trolling the anatomical relationships be-
tween various organs. This article there-
fore touches on the role of homeobox
genes and dietary factors in gut growth
and differentiation.
The development of multicellular ani-
mals is dependent on expression of a
hierarchy of genes that sequentially pro-
vide increasingly detailed positional
information. Many of these genes con-
tain a highly preserved “homeobox”
sequence that codes for a DNA binding
homeo domain. In insects, a group of
such genes—specifying the individual
characteristics of body segments and
known as homeotic selector genes of the
Antp-type (the defining gene is named
Antennapaedia)—are clustered in a com-
plex known as the HOM cluster. These
are expressed topographically in the
same order as they occupy in chromo-
somal DNA. They are conserved strongly
during evolution so that their homo-
logues appear as four paraologous gene
complexes known as Hox complexes
which specify positional information in
mammalian embryos.
Other homeobox genes are scattered
in the genome and of particular interest
are homologues of a Drosophila home-
obox gene called Caudal (Cad). This is
known to be important in determining
anatomical positioning as Drosophila lar-
vae lacking Cad gene products show the
phenotype of deletions of many of the
posterior segments. The first mammalian
Cad homologue (Cdx1) was isolated from
an embryonic mouse cDNA library with
two further members of the Caudal fam-
ily (Cdx2 and Cdx4) having subsequently
been cloned in mice. Cdx3 was originally
identified in the pancreas of hamsters
but has subsequently been shown to be
identical to Cdx2.
Mutation of Cdx1 or 2 results in a skel-
etal homeotic shift, supporting an im-
portant role of the Cad genes in axial
patterning.Homozygous deletion of Cdx2
is a lethal mutation, probably relating to
its importance in the development of
extra-embryonic tissue. The initial re-
ports of the phenotype of Cdx2 +/− (that
is, heterozygote) mice considered that it
resulted in distal bowel tumorigenesis,2
suggesting a role for Cdx2 as a tumour
suppressor gene. More recently, addi-
tional studies suggest that this may have
been a histological misinterpretation
with the “tumours” being areas of
gastric metaplasia.3 It therefore seems
likely that Cdx2 directs endodermal
tissue towards a caudal differentiation
and that Cdx2 haplo insufficient areas
develop as forestomach epithelium. In-
tercalary growth subsequently fills in the
missing tissue types at the discontinuity
between gastric and colonic epithelium
resulting in the polypoidal lesions seen.
In addition to the key role that home-
obox genes play during development, it
is likely that at least some of these genes
also play important functions on prolif-
eration and differentiation during adult
life. Results of manipulating Cdx-1 ex-
pression have given somewhat contra-
dictory results. Transfection studies over-
expressing Cdx-1 in the intestinal cell
line, IEC6, has been reported to increase
proliferation and differentiation4 but also
transformational and tumorigenic
activity.5 However, when the same ap-
proach was used on the human colonic
cell lines HT296 or Caco2 cells,7 it had vir-
tually no effect on proliferation when
transfected on its own but enhanced the
growth inhibitory effect of Cdx-2 in
cotransfected cells.6 An alternative ap-
proach is to reduce the endogenous
levels of Cdx-1 using antisense RNA.
This has been tried and shown to slow
growth of Caco-2 cells,7 providing addi-
tional support for the idea that Cdx-1
plays a role in controlling proliferation.
The data in support of Cdx-2 functioning
as a tumour suppressor gene are some-
what stronger: Cdx2 overexpression re-
duces cell growth in IEC, Caco-2, and
HT29 cells and Cdx2 expression is
decreased in relation to the tumour
grade in human colorectal cancers cells
and in chemically induced tumours in
the rat.8 In addition, the morphology of
transfected IEC and Caco-2 cells is
altered with increased differentiation
and a rise in expression of small intesti-
nal digestive enzymes such as sucrase-
isomaltase.7 Taken together, it appears
likely that Cdx2 functions as a regulator
of intestinal cell differentiation in addi-
tion to its developmental role in embryo-
genesis.
Control of Cdx-1 and 2 expression is
poorly understood although alteration in
oncogenic Ras activation, which is an
early and frequent event in colorectal
cancers, is thought to decrease Cdx-2
expression, acting via the PKC-jun-fos
pathway while increasing Cdx-1 expres-
sion by acting through the Raf-MEK1
pathway (for an excellent review, see
Freud and colleagues9). In the paper
reported in this issue of Gut, Domon-Dell
et al have focused on the interactions
between Cdx-2 expression and butyrate
and found that its presence stimulates
Cdx-2 expression. In their discussion,
they provide further (unpublished)
information regarding potential mecha-
nisms for this effect, such as the possi-
bility of an atypical butyrate response
element by which it might act at a
molecular level although the final an-
swer remains unclear.Whichever mecha-
nisms are involved, it seems likely that
this is an example of direct nutrient
regulation of intestinal cell function and
its findings have applicability beyond the
current study.
The usual impression of a “growth
factor” is a peptide that binds to specific
external receptors, inducing a secondary
signalling cascade resulting in cell prolif-
eration. When considering complex in-
teractions, such as the control of growth
and differentiation of gut cells, it is
important to appreciate that the some-
what arbitrary labelling of a molecule to
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an individual function—for example,
considering “epidermal growth factor”
simply as a stimulant of proliferation—
can be misleading as it is now clear that
such factors have multiple effects. For
example, although they are often consid-
ered separately, the distinction between
cytokines and growth factors are some-
times blurred as the “cytokine” inter-
leukin 8 has been shown to stimulate
migration of human colonic epithelial
cells,10 a process normally associated
with “growth factors”, and peptides nor-
mally considered to be “growth factors”
can influence immunological function.
Similarly, molecules such as glutamine
or butyrate which have been generally
considered to be simple energy provid-
ers, and vitamins such as A and D, which
were at one time thought to have limited
biological functions, are now known to
influence many other activities of the
cell, such as development, differentia-
tion, and proliferation (for example, see
Nagpal and Chandraratna11). The current
study therefore provides further evi-
dence for additional actions of relatively
simple molecules on multiple functions
within a cell, acting through pathways
such as specific DNA response elements.
The distinction between nutrition and
pharmacology is therefore less clear than
it first appears.
Gut 2002;50:447–448
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